Impact of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci among healthy volunteers: a randomised, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26642689

Enrollment

203

Registered

2006-09-04

Start date

2002-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharyngeal carriage of macrolide-resistant streptococci Infections and Infestations Pharyngeal carriage of macrolide-resistant streptococci

Interventions

Volunteers were administered either azithromycin (500 mg) once daily for three days, clarithromycin (500 mg) twice daily for seven days, or a placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults (18 years of age or older, non-pregnant, free of any respiratory tract infection and not having been administered any antibiotic at least in the past three months) were recruited after informed consent.

Exclusion criteria

Exclusion criteria: 1. Less than 18 years 2. Having a respiratory infection 3. Having taken an antibiotic course in the previous three months

Design outcomes

Primary

Measure	Time frame
Changes in proportions of Macrolide-Resistant Streptococcal (MRS) carriage in the oropharynx.	—

Secondary

Measure	Time frame
Variations in the oropharyngeal carriage of macrolide-resistance genes due to macrolide exposure.	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026